Haploidentical Transplantation With Pre-Transplant Immunosuppressive Therapy for Patients With Sickle Cell Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03279094|
Recruitment Status : Recruiting
First Posted : September 12, 2017
Last Update Posted : June 16, 2022
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
This is a study to evaluate the safety and toxicity of a treatment regimen consisting of 2 cycles of pre-transplant immunosuppressive therapy followed by myeloablative preparative regimen and allogeneic hematopoietic stem cell transplantation from a haploidentical donor in patients with sickle cell disease.
The overall goal of this study is to expand the donor pool for hematopoietic stem cell transplantation in sickle cell disease using haploidentical donors, and to develop a non-toxic, myeloablative regimen, with the goal of achieving a consistent donor chimerism utilizing pre-transplant immunosuppressive therapy.
|Condition or disease||Intervention/treatment||Phase|
|Sickle Cell Disease||Biological: Hematopoietic stem cell transplantation||Phase 1|
All patients will receive an haploidentical hematopoietic stem cell transplant with the following conditioning and GvHD prevention:
Pre-transplant immunosuppressive therapy:
2 cycles of Fludarabine and Dexamethasone x 5 days each cycle
rATG daily x 3 days, Fludarabine daily x 6 days and Busulfan daily x 4 days
Cyclophosphamide day +3 and +4, Tacrolimus and Mycophenolate mofetil
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||15 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Pilot Study of Pre-transplant Immunosuppressive Therapy for Haploidentical Transplants in Patients With Sickle Cell Disease|
|Actual Study Start Date :||February 2, 2018|
|Estimated Primary Completion Date :||February 20, 2023|
|Estimated Study Completion Date :||February 20, 2023|
|Experimental: Haploidentical stem cell transplantation||
Biological: Hematopoietic stem cell transplantation
Haploidentical stem cell transplantation with pre-transplant immunosuppressive therapy
- Rate of unacceptable adverse events that are defined as any of the following events that occur from start of pre-transplant immunosuppressive therapy to the first 100 days post HCT: [ Time Frame: 190 days ]
- Rate of death of any causes
- Rate of study discontinuation or early withdrawal
Rate of graft failure
• Primary graft failure is defined as failure to achieve a neutrophil count of 0.5 x 109/L before day +42 or mixed chimerism with failure to achieve <30% Hgb S on electrophoresis after day +180. Secondary graft failure is defined as recovery followed by a sustained loss of initial graft.
- Rate of grade 4 non-hematological toxicities per NCI CTCAE v4.03 that last more than 21 days
- Time to donor neutrophil engraftment [ Time Frame: 24 months ]Day of Neutrophil Engraftment: The first of three consecutive days on which the ANC is ≥0.5x109/L
- Time to donor platelets engraftment [ Time Frame: 24 months ]Day of Platelet engraftment: The first documented day on which the platelet count is >20x109/L unsupported by platelet transfusions for 7 days
- Rate of graft failure [ Time Frame: 24 months ]Primary graft failure is defined as failure to achieve a neutrophil count of 0.5 x 109/L before day +42 or mixed chimerism with failure to achieve <30% Hgb S on electrophoresis after day +180. Secondary graft failure is defined as recovery followed by a sustained loss of initial graft.
- Incidence of acute GvHD (grade II - IV) during the first 100 days after transplantation [ Time Frame: 100 days after transplantation ]
- Incidence of chronic GvHD [ Time Frame: 24 months ]
- Overall survival rate [ Time Frame: 24 months ]• Overall survival: the time from start of PTIS to death, or last follow-up, whichever comes first.
- Event-free survival rate [ Time Frame: 24 months ]• Event-free survival: the time from start of PTIS to death, the unacceptable events, or last follow-up, whichever comes first.
- Disease free survival rate [ Time Frame: 24 months ]• Disease free survival: the time from HCT to death, secondary graft failure, or last follow-up, whichever comes first.
- Immune reconstitution at day 100, 180 and 365 [ Time Frame: 24 months ]• Immune reconstitution: measurement of CD3, CD4, CD8, CD11b, CD14, CD56, CD20/19, FoxP3+ Treg, and memory subsets.
- Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v4.0 from start of pre-transplant immunosuppressive therapy to 24 months post transplant [ Time Frame: 24 months post-transplant ]
- Percent of donor chimerism at 12 and 24 months after HCT [ Time Frame: 12 and 24 months after HCT ]
- Change From Baseline in Pain Scores using Numerical Rating Scale or Faces Pain Rating Scale at 100 days, 6 months and 12 months post-transplant [ Time Frame: 100 days, 6 months and 12 months post-transplant ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||1 Year to 30 Years (Child, Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Diagnosis: Patients with sickle cell anemia (Hgb SS or SB° Thalassemia) with baseline Hgb S more than 60%.
- Disease status:
- Significant neurologic event (stroke) or any neurological deficit lasting > 24 hours; or increased transcranial Doppler velocity (>200 m/s).
- History of one or more episodes of acute chest syndrome (ACS) in the 2-year period preceding enrollment despite the institution of supportive care measures (i.e. asthma therapy and/or hydroxyurea).
- History of one or more severe vaso-occlusive pain crises per year in the 2-year period preceding enrollment despite the institution of supportive care measures (i.e. a pain management plan and/or treatment with hydroxyurea).
- Recurrent priapism requiring medical therapy.
- Osteonecrosis of two or more joints despite the institution of supportive care measures.
- Prior treatment with regular RBC transfusion therapy, defined as receiving 8 or more transfusions per year for > 1 year to prevent vaso-occlusive clinical complications (i.e. pain, stroke, and acute chest syndrome)
- Echocardiograph finding of tricuspid valve regurgitation jet (TRJ) velocity ≥ 2.5 m/sec.
- Ages 1 to 30.
- Child Bearing Potential- Transplantation could be teratogenic and/or lethal to the developing fetus. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation. Should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately.
- Informed Consent/Assent: All subjects must have the ability to understand and the willingness to sign a written informed consent.
- The recipient must have a related donor who is genotypically haploidentical on HLA-A, B, C and DRB1 loci.
- No HLA matched sibling or 10/10 matched unrelated donor is available.
- Any uncontrolled illness including ongoing or active bacterial, viral or fungal infection.
- Patients may not be receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapy.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to any in the pre- or post-transplant regimen.
- Pregnant women are excluded from this study.
- Patients with any active malignancy are ineligible for this study, other than non-melanoma skin cancers.
- Medical problem or neurologic/psychiatric dysfunction which would impair patient ability to be compliant with the medical regimen and to tolerate transplantation or would prolong hematologic recovery which in the opinion of the principal investigator would place the recipient at unacceptable risk.
- Prior autologous or allogeneic transplant.
- Fully HLA-matched related or unrelated donor is available to donate.
- Non-Compliance: Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03279094
|Contact: Anna B. Pawlowska, MDfirstname.lastname@example.org|
|United States, California|
|City of Hope Medical Center||Recruiting|
|Duarte, California, United States, 91010|
|Contact: Mary Suarez, CRC 626-218-5795 email@example.com|
|Principal Investigator: Anna B. Pawlowska, MD|
|Principal Investigator:||Anna B. Pawlowska, MD||City of Hope Medical Center|
|Responsible Party:||City of Hope Medical Center|
|Other Study ID Numbers:||
|First Posted:||September 12, 2017 Key Record Dates|
|Last Update Posted:||June 16, 2022|
|Last Verified:||June 2022|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
|Product Manufactured in and Exported from the U.S.:||No|
Sickle Cell Disease
Hematopoietic stem cell transplantation
Haploidentical stem cell transplantation
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Genetic Diseases, Inborn